Anti-IgE mAb-based treatment has been shown to be beneficial for allergic diseases, asthma, chronic urticaria, food allergies, allergic rhinitis, and allergic bronchopulmonary aspergillosis and can decrease the adverse effects of allergen immunotherapy [292–297]. Here, IGHE is linked to asthma.